ACY 001

Drug Profile

ACY 001

Alternative Names: ACY001; Stem cell therapy-Ischaemia - Arteriocyte

Latest Information Update: 27 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arteriocyte
  • Developer Arteriocyte; Cleveland Clinic Cole Eye Institute
  • Class Anti-ischaemics; Ischaemic heart disorder therapies; Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diabetic retinopathy; Ischaemic heart disorders; Peripheral vascular disorders

Most Recent Events

  • 12 Dec 2016 Arteriocyte is now called Compass Biomedical
  • 02 Apr 2013 Arteriocyte plans a phase II trial for Ischaemic heart disorders in USA
  • 21 Jan 2011 Discontinued - Preclinical for Diabetic retinopathy in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top